Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Therapeutic Advances in Gastroenterology|February 24, 2026
Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCUFrancisco Mesonero, Yamile Zabana, Agnès Fernández-Clotet, et al.
United European Gastroenterology Journal|July 30, 2020
Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's diseaseIago Rodríguez-Lago, Javier Del Hoyo, Alexandre Pérez-Girbés, et al.
Frontiers in Medicine|February 18, 2022
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native PatientsAna Gutiérrez, Pedro Zapater, Elena Ricart, et al.
The American Journal of Gastroenterology|December 14, 2022
Long-Term Outcomes of Biological Therapy in Crohn's Disease Complicated With Internal Fistulizing Disease: BIOSCOPE Study From GETECCUManuel Barreiro-de Acosta, Agnès Fernández-Clotet, Francisco Mesonero, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 15, 2025
Psychomotor Development in Infants Following Maternal Exposure to Biologics: Results From the DUMBO RegistryLaura Palomino, Marta Velasco Rodríguez-Belvís, María José Casanova, et al.
Alimentary Pharmacology & Therapeutics|June 10, 2026
Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA RegistryManuel Barreiro-de Acosta, Yamile Zabana, Laura Nieto-García, et al.
The American Journal of Gastroenterology|January 30, 2023
Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and SafetyMaría Chaparro, Diana Acosta, Cristina Rodríguez, et al.
Journal of Crohn'S & Colitis|May 8, 2019
Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort StudyIvan Guerra, Luis Bujanda, Jesús Castro, et al.
Alimentary Pharmacology & Therapeutics|August 8, 2025
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDACristina Rubín de Célix, Elena Ricart, M Dolores Martín-Arranz, et al.
Alimentary Pharmacology & Therapeutics|June 29, 2024
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registryRocío Ferreiro-Iglesias, Sol Porto Silva, Sandra Marín, et al.
Pageof 8